Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Recruiting Phase 1 Interventional

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

NCT06966024
View directory record Official record
Conditions
Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Interventions
DCC-2812
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

NCT04676529
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions
PXS-5505
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)

NCT01911637
View directory record Official record
Conditions
Healthy
Interventions
VBY-036, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 17, 2026, 3:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers

NCT01364987
View directory record Official record
Conditions
Healthy Subjects, Drug Interactions, Pharmacokinetics of ASP015K
Interventions
ASP015K, Mycophenolate Mofetil
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT03900598
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Interventions
JNJ-67856633
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Duarte, California • Omaha, Nebraska • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

NCT02797821
View directory record Official record
Conditions
Hypophosphatasia
Interventions
Asfotase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Evaluating Patients With Varying Degrees of Renal Function

NCT00398307
View directory record Official record
Conditions
Renal Impairment
Interventions
S-1/Cisplatin
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

NCT02507544
View directory record Official record
Conditions
Carcinoma, Advanced Cancer
Interventions
TRX-818 capsules
Drug
Lead sponsor
TaiRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers

NCT00509132
View directory record Official record
Conditions
Obesity
Interventions
trodusquemine
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers

NCT00169000
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Oct 17, 2026, 3:05 PM EDT
Suspended Phase 4 Interventional

Pharmacokinetic Study of Synera™ in Neonates and Infants

NCT00747669
View directory record Official record
Conditions
Pain
Interventions
lidocaine 70mg and tetracaine 70mg topical patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
Up to 4 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

NCT02829541
View directory record Official record
Conditions
Systemic Lupos Erythematosus, SLE
Interventions
BIIB068, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Not applicable Interventional

Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

NCT02624037
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Individualized Dosage Precision IFX Dashboard
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 45 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin

NCT05929339
View directory record Official record
Conditions
Acute Pain, Chronic Pain, Healthy Volunteer
Interventions
Oxytocin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

NCT02855177
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, PF-06427878
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Glendale, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

NCT01305512
View directory record Official record
Conditions
Solid Tumor in Advanced Stage
Interventions
SPARC1028
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

NCT05159895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-DZD9008
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 17, 2026, 3:05 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 3:05 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

NCT02101554
View directory record Official record
Conditions
Moderate-severe Pain
Interventions
Ages 7-11, ages 12-17
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

NCT00276302
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 17, 2026, 3:05 PM EDT
Completed Not applicable Interventional

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

NCT00056654
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide acetate
Drug
Lead sponsor
Abbott
Industry
Eligibility
Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
55
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Oct 17, 2026, 3:05 PM EDT